Grifols, S.A. (GRFS)
NEUTRALFondamentale
73
Prezzo
$8.05
Capitalizzazione
$5.45B
Parte 1 · Quanto vale l'azienda
Panoramica
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Per questa società non c'è ancora una scheda redazionale
Per questa società non c'è ancora un elenco di concorrenti.
Stato Patrimoniale e Liquidità
Ricavi
$2.01B
Ultimi 12 mesi fino all'ultima trimestrale pubblicata — stima da metriche per azione
Utile Netto
$172M
Ultimi 12 mesi fino all'ultima trimestrale pubblicata — stima da metriche per azione
Free Cash Flow
$573M
Patrimonio Netto Totale
$1.23B
Passività Totali
$9.36B
Rapporto di Liquidità
2.37
Copertura Interessi
-
Debito/EBITDA
5.69
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$12.87
Prezzo Attuale
$8.05
Margine di Sicurezza
+37.5%
Range Fair Value
$8.36 - $17.37
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
12.02
ROE
6.9%
Rapporto P/B
0.98
P/FCF
3.61
Margine Lordo
37.0%
ROIC
8.8%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
8.8%
WACC
3.6%
ROIC − WACC
+5.2 pp
Il ROIC supera il costo del capitale: l'azienda sta creando valore per gli azionisti.
Criteri di Analisi Fondamentale
Superati (16)
- ROIC 8.8%
- Gross Margin 37.0%
- P/FCF 3.61
- P/B Ratio 0.98
- Operating Margin 16.2%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Undervalued)
- ROE 8.4%
- Revenue Growth 5Y 7.1%
- Analyst Consensus 67% Buy
- Earnings Surprise avg 45.6%
- Earnings Quality (OCF/NI) 2.71
- Net Margin Trend 5.3% vs 2.2%
Non superati (4)
- Price CAGR -6.74%
- Debt/Equity ratio
- CapEx intensity
- Piotroski F-Score 2/9
Non disponibili (7)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Piotroski F-Score
Preoccupazioni finanziarie serie
Qualità degli Utili
Alta qualità: utili supportati da cash
Diluizione Azionaria
Riacquisto azioni. Favorevole agli azionisti
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Mr. Jose Ignacio Abia Buenache | CEO & Director | 57 |
| Mr. Rahul Srinivasan | Chief Financial Officer | 48 |
| Mr. Lluis Pons Gomez | Senior Vice President of Strategy & COO Office | 41 |
| Daniel Segarra | Head of Investor Relations & Sustainability and Vice President | - |
| Mr. David Ian Bell | Chief Corporate Affairs & Legal Officer | 71 |
| Mr. Enrique de la Torre | Chief Compliance Officer | 52 |
| Ms. Montse Ribas | Chief Communications and Reputation Officer | 56 |
| Mr. Camille Alpi | Chief Human Resources & Talent Officer | 44 |
| Mr. Vicente Blanquer Torre | Chief Quality Officer | 64 |
| Mr. Ignacio Ramal Subira | Chief Internal Audit & Enterprise Risk Manager | 57 |
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Ultime Notizie
Ultime notizie per GRFS, da Markets Gazette.